文献速递主动脉疾病

编辑推荐——无并发症B型主动脉夹层胸主动脉腔内修复术的最佳时机:系统综述与Meta分析

Editor's Choice - Optimal Timing of Thoracic Endovascular Aortic Repair for Uncomplicated Type B Aortic Dissection: A Systematic Review and Meta-Analysis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-03-05

该系统综述与Meta分析检索MEDLINE、Embase和Cochrane Reviews至2021年4月12日,纳入20篇文章,比较急性期(排除超急性期)与亚急性或慢性期胸主动脉腔内修复术(TEVAR)治疗B型主动脉夹层(TBAD)的效果。结果显示急性期TEVAR在1年随访中主动脉相关事件显著改善,30天和1年全因死亡率无显著差异,作者认为急性期TBAD的TEVAR安全有益,可基于临床、解剖和患者因素考虑早期支架植入。

要点

  • 急性期(排除超急性期)与亚急性或慢性期TEVAR相比,30天和1年全因死亡率无显著差异。
  • 30天术后主动脉相关事件不受干预时机影响,但1年随访中急性期TEVAR的主动脉相关事件显著改善。
  • 作者认为急性期TBAD的TEVAR安全有益,可基于临床、解剖和患者因素考虑早期支架植入。

核心结论

  • 无前瞻性随机对照研究的情况下,有证据表明症状发作后3至14天急性期干预在长期随访中改善主动脉重塑。
  • 作者认为急性期TBAD的TEVAR安全有益,可基于临床、解剖和患者因素考虑早期支架植入。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA文献检索指南,检索MEDLINE、Embase和Cochrane Reviews至2021年4月12日。
  • 纳入20篇文章,由不同作者独立制定纳入和排除标准,使用ROBINS-I工具评估偏倚风险和异质性。
  • 使用RevMan进行Meta分析,采用比值比(OR)及95%置信区间(CI),以I²评估异质性。

主要发现

  • 急性期TEVAR(排除超急性期)与亚急性或慢性期TEVAR相比,30天和1年全因死亡率无显著差异。
  • 30天术后主动脉相关事件不受干预时机影响。
  • 1年随访中主动脉相关事件显著改善, favoring 急性期TEVAR compared with 亚急性或慢性期。
  • 混杂风险高但异质性低。

临床怎么用

  • 作者认为急性期TBAD的TEVAR安全有益,可基于临床、解剖和患者因素考虑早期支架植入。

局限性

  • 无前瞻性随机对照研究。
  • 混杂风险高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type B aortic dissections (TBAD) have a high mortality rate and are challenging to both classify and manage. There is significant evidence supporting the use of early intervention in complicated TBAD with thoracic endovascular aortic repair (TEVAR). Currently, there is equipoise regarding the optimal timing for TEVAR in TBAD. This systematic review answers whether early TEVAR in the hyperacute or acute phase of the disease has improved aorta related events in the one year follow up period with no change in mortality rate when compared with TEVAR in the subacute or chronic phase. DATA SOURCES: A systematic review and meta-analysis was performed with Preferred Reporting Items for Systematic Reviews and Meta-Analyses literature search guidelines for MEDLINE, Embase, and Cochrane Reviews until 12 April 2021. Inclusion and exclusion criteria targeting the review objective and high quality research were employed by separate authors. REVIEW METHODS: These studies were then reviewed for suitability, risk of bias, and heterogeneity using the ROBINS-I tool. Results were extracted for the meta-analysis with RevMan using odds ratios with 95% confidence intervals with I2 used to assess heterogeneity. RESULTS: Twenty articles were included. A meta-analysis showed no significant difference between acute phase TEVAR (excluding the hyperacute phase) and subacute or chronic phase TEVAR for the all cause 30 day and one year mortality rates. Aorta related events in the 30 day post-operative period were unaffected by the timing of intervention but had significant improvement in aorta related events in the one year follow up favouring TEVAR in the acute phase compared with subacute or chronic phase. Risk of confounding was high but with low heterogeneity. CONCLUSION: Without prospective randomised controlled studies, it is evident that there is improved aortic remodelling in long term follow up with intervention in the acute setting from three to 14 days after symptom onset. This suggests that TEVAR in the acute period of TBAD is both safe and beneficial, and can be considered for early stent grafting based on clinical, anatomical and patient factors.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Saricilar EC, Patel K, Gatmaitan R, et al. Editor's Choice - Optimal Timing of Thoracic Endovascular Aortic Repair for Uncomplicated Type B Aortic Dissection: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2023. PMID: 36871923. doi:10.1016/j.ejvs.2023.02.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。